Contents
Bioidentical hormone replacement therapy, commonly called BHRT, uses hormones that have the same chemical and molecular structure as hormones naturally produced by the human body. Depending on a person’s symptoms, medical history, age, reproductive status, and treatment goals, therapy may involve estradiol, progesterone, testosterone, or another hormone.
The word bioidentical does not indicate whether a medication is FDA-approved, custom compounded, safer, more effective, or appropriate for a particular person. Some FDA-approved estradiol and micronized progesterone medications are considered bioidentical. Compounded medications may also contain bioidentical hormones, but they are not reviewed and approved by the FDA in the same way as commercially manufactured prescription products.
Personalized hormone care begins with symptoms, medical history, current medications, reproductive goals, preventive screening, and individual risk factors. Laboratory testing can add objective information, identify conditions that resemble hormone-related symptoms, establish useful baseline measurements, and support treatment monitoring.
Ulta Lab Tests provides direct access to many hormone, thyroid, metabolic, nutrient, and treatment-monitoring tests. These results can help patients prepare for informed discussions with qualified healthcare professionals. Laboratory testing provides health information but does not replace a medical evaluation, diagnosis, prescription, or individualized treatment plan.
A bioidentical hormone has the same molecular structure as a hormone produced by the human body. Common examples include:
BHRT is not one standardized treatment. Hormone medications differ in their ingredients, dosage, route of administration, absorption, manufacturing standards, duration of action, and supporting clinical evidence.
Hormones may be delivered through oral capsules, transdermal patches, gels, sprays, vaginal preparations, injections, or implanted pellets. The delivery method matters because it influences absorption, metabolism, peak hormone concentrations, duration of action, potential adverse effects, and the appropriate timing of laboratory measurements.
FDA-approved hormone products are manufactured in standardized doses and undergo regulatory review for quality, safety, effectiveness, and labeling. Compounded medications are prepared for an individual patient and may be useful when an approved medication cannot meet a specific medical need, such as an allergy to an inactive ingredient or the need for a dosage form that is not commercially available.
However, compounded drugs are not FDA-approved before marketing. The FDA does not evaluate compounded medications for safety, effectiveness, quality, or consistency in the same manner as approved medications. Inadequate compounding practices may produce contamination or an incorrect amount of active medication.
Professional medical organizations generally recommend using FDA-approved hormone products when an appropriate approved option is available.
On February 12, 2026, the FDA approved labeling changes for an initial group of six menopausal hormone therapy products. Risk statements concerning cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warnings for those products. The endometrial cancer warning remains important for systemic estrogen-alone therapy in women who still have a uterus.
This change does not mean that hormone therapy is risk-free or suitable for everyone. Treatment decisions should still consider age, time since menopause, symptoms, medical history, family history, formulation, route of administration, dosage, and the labeling for the specific medication.
Hormone-related symptoms can be significant, but most are not specific to one hormone. Fatigue, sleep problems, reduced sexual desire, mood changes, weight changes, irregular periods, brain fog, reduced stamina, and changes in physical performance may have several overlapping causes.
Potential contributors include:
A personalized evaluation asks two essential questions:
This approach helps avoid treating a laboratory number while overlooking the person’s broader health picture.
| Symptom or Risk Factor | What It May Suggest | Related Lab Tests |
|---|---|---|
| Hot flashes and night sweats | Menopause transition, medication effects, thyroid dysfunction, infection, or another health condition | TSH Test, Free T4 Test, and selected FSH and Estradiol testing |
| Irregular or absent menstrual periods | Perimenopause, pregnancy, thyroid disease, elevated prolactin, polycystic ovary syndrome, or ovarian insufficiency | Pregnancy Blood Test, TSH, Prolactin, FSH, LH, and Estradiol |
| Fatigue and reduced stamina | Anemia, thyroid disease, sleep problems, iron deficiency, metabolic disease, nutrient deficiency, or low testosterone in appropriately selected men | Complete Blood Count, Ferritin, TSH, Free T4, Total Testosterone, and Hemoglobin A1c |
| Reduced libido | Menopause symptoms, pain, medication effects, relationship factors, depression, testosterone deficiency in men, or hypoactive sexual desire disorder | Total Testosterone, Free Testosterone, SHBG, Prolactin, and thyroid testing when clinically appropriate |
| Erectile dysfunction | Vascular disease, diabetes, medication effects, low testosterone, neurologic causes, or psychological factors | Morning Total Testosterone, Hemoglobin A1c, Lipid Panel, and Prolactin |
| Loss of muscle or strength | Aging, inactivity, inadequate nutrition, chronic illness, thyroid dysfunction, or testosterone deficiency | Morning Total Testosterone, CBC, Comprehensive Metabolic Panel, and thyroid tests |
| Vaginal dryness or painful intercourse | Genitourinary syndrome of menopause, infection, a dermatologic condition, or a pelvic-floor disorder | Evaluation is frequently based on symptoms and examination; infection testing may be appropriate when indicated |
| Unexplained weight change | Thyroid dysfunction, medication effects, sleep disruption, calorie changes, fluid retention, or metabolic disease | TSH, Free T4, Comprehensive Metabolic Panel, Hemoglobin A1c, and Lipid Panel |
| Breast discharge or unexplained headaches | Elevated prolactin or a pituitary disorder | Prolactin Test and thyroid testing, followed by clinician-directed evaluation |
| Current testosterone therapy | Need to evaluate treatment response, excessive hormone exposure, rising hematocrit, or prostate-related considerations | Total and Free Testosterone with SHBG, CBC with Hematocrit, and PSA Total when appropriate |
Safety note: Sudden chest pain, shortness of breath, stroke symptoms, one-sided leg swelling, severe neurologic symptoms, heavy or unexplained vaginal bleeding, or other acute and concerning symptoms require prompt medical attention rather than routine direct-access laboratory testing.
Not always. For many women older than 45 who have typical menstrual changes and menopausal symptoms, perimenopause can often be identified from age, symptoms, and menstrual history. Routine hormone testing may not be necessary because estrogen and FSH levels can change considerably throughout the menopause transition.
Testing may be more useful when:
A single FSH, Estradiol, or Progesterone result should not be interpreted as a complete picture of menopausal status. Results may be affected by menstrual-cycle timing, hormonal contraception, pregnancy, hormone therapy, recent illness, medications, and the laboratory method.
Testosterone deficiency in men requires a more structured evaluation. Professional guidelines recommend diagnosing hypogonadism only when a man has compatible symptoms or signs and consistently low testosterone concentrations.
A low Morning Total Testosterone Test result should generally be repeated on a separate morning, preferably while fasting and when the person is not experiencing an acute illness.
When low testosterone is confirmed, additional tests may help identify the underlying cause:
Testosterone therapy can suppress sperm production. Men who are planning fertility should discuss this issue with a qualified healthcare professional before considering treatment.
Laboratory testing can answer targeted questions, but every test has limitations.
Hormone concentrations naturally vary. Properly timed repeat tests performed with a consistent laboratory method may provide more useful information than reacting to one unexpected result.
The goal is not to order as many tests as possible. The goal is to select the appropriate test, collect it at the right time, and use it to answer a clearly defined health question.
| Lab Test | What It Measures | Why It May Be Relevant | Important Limitations |
|---|---|---|---|
| Estradiol Test | The primary circulating estrogen | May support selected evaluations of ovarian function, menstrual changes, menopause questions, or hormone exposure | Estradiol varies by cycle phase and treatment timing; one result rarely establishes menopause or determines an appropriate dosage |
| FSH Test | Follicle-stimulating hormone produced by the pituitary gland | May help evaluate ovarian insufficiency, menopause in selected situations, fertility questions, or testicular function | FSH can fluctuate significantly during perimenopause and must be interpreted in context |
| LH Test | Luteinizing hormone produced by the pituitary gland | May support reproductive evaluation and can help distinguish primary from secondary hypogonadism in men | LH is released in pulses and may vary with menstrual-cycle timing |
| Progesterone Test | Progesterone produced after ovulation and during pregnancy | May help document ovulation or answer a defined reproductive-health question | Results depend heavily on menstrual-cycle timing and are not routinely used to adjust menopausal hormone therapy |
| Total Testosterone Test | Total circulating testosterone, including bound and unbound hormone | Central to evaluating suspected testosterone deficiency in men and selected androgen concerns in women | Men generally require two separate morning measurements before a diagnosis is considered |
| Free Testosterone Test | The portion of circulating testosterone that is not tightly bound to proteins | May be helpful when total testosterone is borderline or SHBG is abnormal | Results depend on assay quality, calculation method, SHBG, and the clinical context |
| Sex Hormone-Binding Globulin Test | A protein that binds testosterone and estradiol | Helps explain differences between total and available hormone concentrations | SHBG may be affected by age, thyroid status, liver health, obesity, insulin, and medications |
| DHEA-S Test | An androgen produced primarily by the adrenal glands | May help evaluate androgen excess, selected adrenal conditions, or unexplained hormone-related symptoms | DHEA-S normally declines with age; a low result alone does not establish a need for supplementation |
| Prolactin Test | A pituitary hormone involved in lactation and reproductive function | May help evaluate absent periods, breast discharge, infertility, low testosterone, or a suspected pituitary condition | Stress, sleep, medications, exercise, and specimen conditions may influence the result |
| Lab Test | Why It May Matter |
|---|---|
| TSH Test and Free T4 Test | Thyroid dysfunction may resemble menopause or low-testosterone symptoms, including fatigue, mood changes, weight changes, temperature intolerance, and menstrual irregularity. |
| Complete Blood Count with Differential and Platelets | A CBC can identify patterns associated with anemia and provides hematocrit information that is important before and during testosterone therapy. |
| Ferritin Test and Iron and Total Iron-Binding Capacity Test | These tests may help investigate fatigue, hair shedding, reduced exercise tolerance, heavy menstrual bleeding, or suspected iron deficiency. |
| Comprehensive Metabolic Panel | A CMP measures liver enzymes, kidney-related markers, electrolytes, glucose, and proteins that may affect overall treatment planning. |
| Lipid Panel Test | A lipid panel measures cholesterol and triglyceride-related markers and helps establish a cardiovascular-risk baseline. |
| Hemoglobin A1c Test | Hemoglobin A1c estimates average glucose exposure over approximately two to three months and may identify prediabetes or diabetes. |
| PSA Total Test | PSA testing may support prostate-risk discussions and monitoring in appropriately selected men considering or receiving testosterone therapy. |
| Vitamin B12 Test | Vitamin B12 testing may help evaluate selected cases of fatigue, anemia, numbness, tingling, or nutritional risk. |
| Vitamin D 25-Hydroxy Test | Vitamin D testing may provide information about vitamin D status, bone-health support, and selected nutritional concerns. |
| Pregnancy Blood Test | Pregnancy should be considered when menstrual periods are late or absent and pregnancy remains possible. |
Testing should be selected according to the person’s symptoms and health questions rather than ordered as a universal package.
Before hormone therapy is considered, an evaluation commonly includes:
Potential baseline tests may include a TSH Test, Complete Blood Count, Comprehensive Metabolic Panel, Hemoglobin A1c Test, or Lipid Panel when clinically appropriate.
For women, targeted testing may include:
For men, targeted testing may include:
The appropriate monitoring plan depends on the hormone, formulation, dosage, route, symptoms, and medical history.
Possible tests include:
Additional testing may be appropriate when:
More testing is not always better. Each test should have a defined purpose and a plan for how the result will be interpreted.
Menopausal hormone therapy is most commonly used for bothersome hot flashes, night sweats, genitourinary syndrome of menopause, and selected bone-health indications.
For many healthy women who begin treatment before age 60 or within approximately 10 years of menopause onset, professional organizations consider the overall benefit-risk balance favorable when treatment is individualized.
A woman who still has a uterus generally requires adequate endometrial protection when using systemic estrogen. Estrogen without an appropriate progestogen can stimulate the uterine lining and increase the risk of endometrial hyperplasia and cancer.
Testosterone therapy for women requires separate caution. The principal evidence-based indication is hypoactive sexual desire disorder in appropriately evaluated postmenopausal women. A low testosterone measurement does not diagnose that condition, and testosterone has not been established as a general treatment for fatigue, brain fog, mood changes, weight gain, muscle loss, or anti-aging.
Low energy, reduced libido, erectile dysfunction, increased body fat, reduced strength, and poor sleep do not automatically indicate testosterone deficiency. Obesity, diabetes, sleep apnea, medications, depression, chronic illness, and normal aging may contribute to similar symptoms.
Before testosterone treatment is considered, an evidence-based evaluation generally includes:
Routine testosterone screening is generally not recommended for otherwise healthy men who do not have suggestive symptoms or signs.
Saliva testing is sometimes marketed as a way to create an exact customized hormone formula. However, major professional organizations report that there is insufficient evidence supporting salivary hormone testing for customizing compounded hormone doses.
Hormone concentrations vary, salivary assays may lack standardization, and the relationship between a salivary concentration, tissue exposure, symptoms, and treatment safety is not sufficiently established for routine dose adjustment.
Serum blood testing also has limitations, but standardized blood testing is better established for defined clinical questions such as evaluating male hypogonadism, measuring thyroid function, investigating elevated prolactin, or monitoring hematocrit during testosterone treatment.
A laboratory reference range describes values observed in a comparison population using a particular testing method. It does not automatically identify the best value for every patient or prove that hormone treatment is needed.
Results may vary according to:
Some hormone programs promote narrow “optimal” ranges that are not supported by widely accepted clinical guidelines. A result may fall within a laboratory reference range while symptoms still deserve investigation. Conversely, a result outside the reference range does not automatically mean that hormone treatment is appropriate.
Temporary hormone changes may occur because of illness, sleep deprivation, stress, calorie restriction, strenuous exercise, medication use, or specimen timing. Unexpected results may need to be repeated before a treatment decision is made.
A normal hormone result does not mean that symptoms should be dismissed. It may indicate that another possible cause should be investigated instead of automatically increasing a hormone dose.
Always review the preparation requirements for the specific test being ordered.
Ulta Lab Tests enables patients to order many laboratory tests directly online where available. Testing is performed through established laboratory networks, including Quest Diagnostics where applicable, and patients can review transparent pricing before ordering.
No insurance is required. HSA or FSA payment may be available for eligible purchases, and results are delivered securely through an online account.
Patients can use their results to prepare for more informed conversations with physicians and other qualified healthcare professionals. Direct-access testing may be useful when a patient needs:
Explore relevant Ulta Lab Tests options:
Ordering a laboratory test does not mean that hormone therapy is appropriate. Prescription decisions and changes to hormone medications require qualified clinical oversight.
BHRT uses hormones that are structurally identical to hormones naturally produced by the body. Traditional hormone therapy may include bioidentical or non-bioidentical formulations. The distinction is not simply natural versus synthetic. Many FDA-approved estradiol and micronized progesterone products are bioidentical, while custom-compounded BHRT products are not individually FDA-approved before marketing.
The term bioidentical does not establish safety. Safety depends on the hormone, dosage, route, duration, product quality, treatment indication, age, medical history, and individual risk factors. Professional medical organizations do not consider custom-compounded hormones inherently safer or more effective than FDA-approved bioidentical products.
Possible tests include Estradiol, FSH, LH, Total Testosterone, Free Testosterone, SHBG, Prolactin, TSH, Free T4, CBC, CMP, Lipid Panel, and Hemoglobin A1c. The appropriate selection depends on the patient and clinical question.
Many women older than 45 with typical symptoms and menstrual changes do not need hormone testing to identify perimenopause. Hormone levels may fluctuate considerably during this stage. Testing may be useful when symptoms begin early, menstrual periods stop unexpectedly, pregnancy is possible, or another endocrine condition is suspected.
No validated blood test can calculate a perfect personalized BHRT dose. Laboratory results may establish a baseline, identify unexpectedly high or low exposure, and support safety monitoring. Treatment decisions should also consider symptoms, adverse effects, medical history, formulation, route of administration, and evidence-based prescribing guidance.
Guidelines generally recommend two separate Morning Total Testosterone Tests in a man with compatible symptoms or signs. When low testosterone is confirmed, Free Testosterone, SHBG, LH, FSH, Prolactin, a CBC with Hematocrit, and selected prostate or metabolic tests may provide additional information.
Monitoring may include Total and Free Testosterone with SHBG, a CBC with Hematocrit, clinical response, and potential adverse effects. A PSA Total Test may be appropriate depending on age, prostate risk, and shared decision-making. Collection timing should be matched to the prescribed testosterone formulation.
Testosterone is not established as a general treatment for fatigue, brain fog, mood symptoms, weight gain, or anti-aging in women. The principal evidence-based indication is hypoactive sexual desire disorder in appropriately evaluated postmenopausal women. A testosterone result alone should not be used to diagnose that condition.
Professional medical organizations do not recommend using saliva hormone testing to customize compounded menopausal hormone doses. Hormone levels fluctuate, saliva assays have standardization and interpretation limitations, and there is inadequate evidence that saliva-guided dosing improves treatment effectiveness or safety.
There is no universal schedule. Timing depends on the hormone, formulation, dosage, reason for treatment, symptoms, health risks, and clinician’s monitoring plan. Follow-up testing may be performed after starting or changing therapy and periodically thereafter. Testing should be frequent enough to answer a clinical question without chasing unvalidated optimal ranges.
Ulta Lab Tests provides direct online access to many hormone and monitoring tests where available. Patients order online, visit an authorized collection location, and receive secure online results. Direct-access testing can provide useful information, but results do not replace a clinician’s evaluation, diagnosis, prescription, or treatment plan.
Review the result in context before drawing conclusions. Consider the collection time, menstrual-cycle phase, medication timing, supplements, fasting status, illness, and laboratory reference range. Some results should be repeated for confirmation. Markedly abnormal results, new symptoms, or unexpected findings during hormone therapy should be reviewed promptly with a qualified healthcare professional.
Bioidentical hormone replacement therapy may be part of individualized care for appropriately selected women and men, but the term bioidentical should not be confused with proven safety, FDA approval, or guaranteed results.
A responsible approach combines symptoms, medical history, age, reproductive goals, preventive care, evidence-based treatment indications, and focused laboratory testing. For women experiencing typical perimenopause, symptoms and menstrual history may be more informative than one fluctuating hormone result. For men with suspected testosterone deficiency, repeat morning testosterone testing is an important part of the evaluation.
Laboratory testing is most valuable when it answers a defined question: Is another condition contributing to the symptoms? Is testosterone consistently low? Is treatment producing unexpectedly high exposure? Is hematocrit increasing? Are thyroid, glucose, lipid, blood-count, or nutrient markers affecting the broader health picture?
Explore hormone testing through Ulta Lab Tests and use your results to prepare for an informed discussion with a qualified healthcare professional. Do not begin, stop, or change hormone medication based only on laboratory results without appropriate medical guidance.
Bioidentical hormone replacement therapy uses hormones that have the same molecular structure as hormones naturally produced by the human body. Bioidentical hormones may be FDA-approved or custom compounded, and the term does not by itself establish safety, effectiveness, or manufacturing quality.
Related laboratory tests: Estradiol, FSH, LH, Progesterone, Total Testosterone, Free Testosterone, SHBG, DHEA-S, Prolactin, TSH, Free T4, CBC, CMP, Lipid Panel, Hemoglobin A1c, Ferritin, and PSA Total when appropriate.
Ulta Lab Tests helps patients access many relevant laboratory tests online and use their secure results to prepare for informed conversations with qualified healthcare professionals.
Laboratory testing is informational and should not replace medical evaluation, diagnosis, prescribing, or professional review.
These Ulta Lab Tests pages cover the principal sex and reproductive hormones discussed in the article.
Thyroid testing is included because thyroid-related symptoms may overlap with symptoms often attributed to changing sex hormones. Ulta Lab Tests maintains individual and combined thyroid-test pages.
The CBC page and Ulta’s general-health categories identify blood-count and iron-related testing among the relevant health assessments discussed in the article.
The CMP product page and Ulta’s general-health and heart-health areas support these links.
Both individual product pages and the Vitamin and Mineral health area are currently available on Ulta Lab Tests.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
